Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 12/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.38 |
| ▸ | FAP | Q12884 | 3/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2898008 | 1.00 | GPR119 (0.46) | GPR119KCNH2DPP4DPP8DPP9 | |
| SCHEMBL2897850 | 0.93 | GPR119 (0.45) | GPR119KCNH2DPP4DPP8DPP9 | |
| SCHEMBL2897854 | 0.93 | GPR119 (0.45) | GPR119KCNH2DPP4DPP8DPP9 | |
| SCHEMBL2898469 | 0.93 | GPR119 (0.41) | GPR119KCNH2DPP4DPP8DPP9 | |
| SCHEMBL2898465 | 0.93 | GPR119 (0.41) | GPR119KCNH2DPP4DPP8DPP9 | |
| SCHEMBL2897623 | 0.93 | GPR119 (0.40) | GPR119KCNH2DPP4DPP8DPP9 | |
| SCHEMBL2897619 | 0.93 | GPR119 (0.40) | GPR119KCNH2DPP4DPP8DPP9 | |
| SCHEMBL8076641 | 0.92 | GPR119 (0.47) | GPR119KCNH2HRH3 | |
| SCHEMBL2895424 | 0.90 | GPR119 (0.47) | GPR119KCNH2DPP4DPP8DPP9 | |
| SCHEMBL2895426 | 0.90 | GPR119 (0.47) | GPR119KCNH2DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | claimed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, DPP4, DPP9 | GPR119 1/4885KCNH2 2784/4885DPP4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.